 Epoprostenol
"Epoprostenol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
| Descriptor ID |
D011464
|
| MeSH Number(s) |
D10.251.355.255.550.550.500 D23.469.050.175.725.550.500
|
| Concept/Terms |
Epoprostenol- Epoprostenol
- PGI2
- Prostaglandin I2
- Prostacyclin
- Prostaglandin I(2)
- Epoprostanol
- PGX
Epoprostenol Sodium- Epoprostenol Sodium
- Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
|
Below are MeSH descriptors whose meaning is more general than "Epoprostenol".
Below are MeSH descriptors whose meaning is more specific than "Epoprostenol".
This graph shows the total number of publications written about "Epoprostenol" by people in this website by year, and whether "Epoprostenol" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 1990 | 1 | 1 | 2 | | 1991 | 1 | 1 | 2 | | 1992 | 0 | 1 | 1 | | 1993 | 0 | 2 | 2 | | 1994 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 2 | 1 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 2 | 3 | | 2000 | 1 | 1 | 2 | | 2002 | 1 | 1 | 2 | | 2003 | 3 | 1 | 4 | | 2004 | 3 | 2 | 5 | | 2005 | 2 | 2 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 0 | 2 | | 2008 | 2 | 0 | 2 | | 2009 | 4 | 4 | 8 | | 2010 | 2 | 3 | 5 | | 2011 | 0 | 1 | 1 | | 2012 | 5 | 1 | 6 | | 2013 | 3 | 2 | 5 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 2 | 3 | | 2017 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Epoprostenol" by people in Profiles.
-
Dwyer-Nield L, Hickey GA, Friedman M, Choo K, McArthur DG, Tennis MA, New ML, Geraci M, Keith RL. The Second-Generation PGI2 Analogue Treprostinil Fails to Chemoprevent Tumors in a Murine Lung Adenocarcinoma Model. Cancer Prev Res (Phila). 2017 Nov; 10(11):671-679.
-
Parker DK, Shen S, Zheng J, Ivy DD, Crotwell DN, Hotz JC, DiBlasi RM. Inhaled Treprostinil Drug Delivery During Mechanical Ventilation and Spontaneous Breathing Using Two Different Nebulizers. Pediatr Crit Care Med. 2017 Jun; 18(6):e253-e260.
-
Held N, Little N, Krantz MJ, Stauffer BL. Refractory Cardiogenic Shock from Right Ventricular Infarction Successfully Managed with Inhaled Epoprostenol. Am J Case Rep. 2017 Mar 16; 18:271-275.
-
Tennis MA, New ML, McArthur DG, Merrick DT, Dwyer-Nield LD, Keith RL. Prostacyclin reverses the cigarette smoke-induced decrease in pulmonary Frizzled 9 expression through miR-31. Sci Rep. 2016 06 24; 6:28519.
-
Palatnik A, Xin H, Su EJ. Dichotomous effects of aryl hydrocarbon receptor (AHR) activation on human fetoplacental endothelial cell function. Placenta. 2016 08; 44:61-8.
-
Yun B, Lee H, Jayaraja S, Suram S, Murphy RC, Leslie CC. Prostaglandins from Cytosolic Phospholipase A2a/Cyclooxygenase-1 Pathway and Mitogen-activated Protein Kinases Regulate Gene Expression in Candida albicans-infected Macrophages. J Biol Chem. 2016 Mar 25; 291(13):7070-86.
-
Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I. Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc. 2015 Jun; 12(6):960.
-
Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc. 2015 Feb; 12(2):269-73.
-
Capra V, Rovati GE, Mangano P, Buccellati C, Murphy RC, Sala A. Transcellular biosynthesis of eicosanoid lipid mediators. Biochim Biophys Acta. 2015 Apr; 1851(4):377-82.
-
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 07; 33(7):689-97.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|